

# Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2020

<https://marketpublishers.com/r/CB9F793CB6DEN.html>

Date: September 2020

Pages: 162

Price: US\$ 2,000.00 (Single User License)

ID: CB9F793CB6DEN

## Abstracts

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2020, provides an overview of the Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline landscape.

Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide

covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 5, 1, 21 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:**

Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## **SCOPE**

The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy (Toxicology).

The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Chemotherapy Induced Peripheral Neuropathy - Overview

Chemotherapy Induced Peripheral Neuropathy - Therapeutics Development

Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment

Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics  
Development

Chemotherapy Induced Peripheral Neuropathy - Drug Profiles

Chemotherapy Induced Peripheral Neuropathy - Dormant Projects

Chemotherapy Induced Peripheral Neuropathy - Discontinued Products

Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H2 2020

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Algo Therapeutix SAS, H2 2020

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Annji Pharmaceutical Co Ltd, H2 2020

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Apexian Pharmaceuticals Inc, H2 2020

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aphios Corp, H2 2020

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aptinyx Inc, H2 2020

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Asahi Kasei Pharma Corp, H2 2020

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Bristol-Myers Squibb Co, H2 2020

Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H2 2020

Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

### COMPANIES MENTIONED

Achelios Therapeutics Inc

Algo Therapeutix SAS

Annji Pharmaceutical Co Ltd

Apexian Pharmaceuticals Inc

Aphios Corp

Aptinyx Inc

Asahi Kasei Pharma Corp

Bristol-Myers Squibb Co

Candel Therapeutics

Disarm Therapeutics Inc

Emerald Bioscience Inc

Exodos Life Sciences Limited Partnership

Immune Pharmaceuticals Inc

KannaLife Sciences Inc

Kineta Inc

Kyorin Pharmaceutical Co Ltd

MAKScientific LLC

Medifron DBT Co Ltd

Metys Pharmaceuticals AG

Mundipharma International Ltd

NeurExo Sciences LLC  
Osmol Therapeutics Inc  
Pharmatrophix Inc  
PledPharma AB  
Regulonix LLC  
Senzer Ltd  
SiteOne Therapeutics Inc  
Sonnet BioTherapeutics Holdings Inc  
Sova Pharmaceuticals Inc  
Stealth BioTherapeutics Corp  
Toray Industries Inc  
Trevena Inc  
WEX Pharmaceuticals Inc  
Winsantor Inc  
YD Life Science Co



## I would like to order

Product name: Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/CB9F793CB6DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CB9F793CB6DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970